Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Matinas Biopharma Hl (MTNB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 252,042
  • Shares Outstanding, K 90,990
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,600 K
  • 36-Month Beta 0.78
  • Price/Sales 25,204.20
  • Price/Cash Flow N/A
  • Price/Book 17.90

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.02 +37.13%
on 05/31/17
3.06 -9.48%
on 05/25/17
-0.28 (-9.18%)
since 05/23/17
3-Month
1.50 +84.67%
on 03/24/17
3.20 -13.44%
on 04/24/17
-0.04 (-1.42%)
since 03/23/17
52-Week
0.60 +361.67%
on 06/24/16
3.99 -30.58%
on 03/02/17
+2.13 (+332.81%)
since 06/23/16

Most Recent Stories

More News
Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis

Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced the presentation of...

MTNB : 2.77 (+9.92%)
Matinas BioPharma to Present at the 2017 Jefferies Global Healthcare Conference

Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour,...

MTNB : 2.77 (+9.92%)
Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance

Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that it has appointed...

MTNB : 2.77 (+9.92%)
Matinas BioPharma Appoints Eric J. Ende, M.B.A, M.D. to its Board of Directors

Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today the appointment of...

MTNB : 2.77 (+9.92%)
Matinas BioPharma to Present at 29th Annual ROTH Conference

Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that Jerome D. Jabbour,...

MTNB : 2.77 (+9.92%)
Matinas BioPharma Announces Positive Preclinical Efficacy Results of MAT2501 in an In Vitro Model of Mycobacterium abscessus Infection

Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced positive efficacy results...

MTNB : 2.77 (+9.92%)
Matinas BioPharma Provides Business Outlook and Sets Corporate Milestones for 2017

-- Several data milestones anticipated during 1H 2017

MTNB : 2.77 (+9.92%)
Matinas BioPharma to Present at Noble Capital Markets' Thirteenth Annual Investor Conference

Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour,...

MTNB : 2.77 (+9.92%)
Matinas BioPharma to Present at Biotech Showcase(TM) 2017

Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour,...

MTNB : 2.77 (+9.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Matinas BioPharma Holdings, Inc. is a development stage biopharmaceutical company. It focuses on identifying and developing pharmaceutical products for the treatment of abnormalities in blood lipids and the treatment of cardiovascular and metabolic diseases. The Company primarily focuses on developing...

See More

Support & Resistance

2nd Resistance Point 3.13
1st Resistance Point 2.95
Last Price 2.77
1st Support Level 2.43
2nd Support Level 2.09

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.